Serum Uric Acid Levels and Incident Chronic Kidney Disease in Patients With Type 2 Diabetes and Preserved Kidney Function
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Recent studies have suggested an association between hyperuricemia and adverse renal outcomes in nondiabetic populations. Data on the relationship between hyperuricemia and the risk of incident chronic kidney disease (CKD) in type 2 diabetic patients with normal or near-normal kidney function are lacking. We determined whether baseline serum uric acid levels predict the subsequent development of CKD in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We followed 1,449 type 2 diabetic patients with normal kidney function and without overt proteinuria for 5 years for the occurrence of incident CKD (defined as overt proteinuria or estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2). RESULTS: During a 5-year follow-up period, 194 (13.4%) patients developed incident CKD. The cumulative incidence of CKD was significantly greater in patients with hyperuricemia than in those without hyperuricemia (29.5 vs. 11.4%, P < 0.001). In univariate logistic regression analysis, the presence of hyperuricemia roughly doubled the risk of developing CKD (odds ratio [OR] 2.55 [95% CI 1.71–3.85], P < 0.001). After adjusting for age, sex, BMI, smoking status, diabetes duration, systolic blood pressure, antihypertensive treatment, insulin therapy, HbA1c, eGFR, and albuminuria, hyperuricemia was associated with an increased risk of incident CKD (adjusted OR 2.10 [1.16–3.76], P < 0.01). In continuous analyses, a 1-SD increment in the serum uric acid level was significantly associated with a 21% increased risk of CKD. CONCLUSIONS: In type 2 diabetic individuals with preserved kidney function, hyperuricemia seems to be an independent risk factor for the development of incident CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hyperuricemia may induce kidney inflammation and has been reported to be a risk factor for incident DKD in T2DM (43).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [43]
In the citing paper
“Hyperuricemia has been associated with kidney inflammation, and various observational studies documented a strong linear association between higher plasma uric acid levels and progressive kidney function loss (Zoppini et al., 2012).”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Zoppini et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 1×
“Nonetheless, current GFR estimates facilitate the detection, evaluation, and management of CKD, and many organizations recommend the use of prediction equations for the evaluation of kidney function in large epidemiologic studies and in clinical practice (1,10,25,26).”
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992
Fang, J., & Alderman, M. H. (2000) · JAMA · doi:10.1001/jama.283.18.2404 · Cited by 1,513
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
A Role for Uric Acid in the Progression of Renal Disease
Kang, D.-H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., Truong, L., Harris, R., & Johnson, R. J. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034910.58454.fd · Cited by 1,304
Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study
Culleton, B. F., Larson, M. G., Kannel, W. B., & Levy, D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-1-199907060-00003 · Cited by 1,282
Siu, Y.-P., Leung, K.-T., Tong, M. K.-H., & Kwan, T.-H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.006 · Cited by 834 · cited 1×
“Two small prospective, randomized, controlled trials involving nondiabetic and diabetic patients with hyperuricemia and CKD, who were randomly assigned to treatment with allopurinol or to continue with the usual therapy for 12–24 months, demonstrated that the allopurinol group showed less kidney dysfunction compared w…”
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580210 · Cited by 834 · cited 1×
“Two small prospective, randomized, controlled trials involving nondiabetic and diabetic patients with hyperuricemia and CKD, who were randomly assigned to treatment with allopurinol or to continue with the usual therapy for 12–24 months, demonstrated that the allopurinol group showed less kidney dysfunction compared w…”
Research works printed but not linked: 1
- Brenner, 2004, Diabetic nephropathy, 1777
Cited by
Uric acid and chronic kidney disease: which is chasing which?
Johnson, R. J., Nakagawa, T., Jalal, D., Sanchez-Lozada, L. G., Kang, D.-H., & Ritz, E. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft029 · Cited by 654
Serum uric acid and the risk of cardiovascular and renal disease
Borghi, C., Rosei, E. A., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J. T., Manolis, A. J., Perez-Ruiz, F., & Mancia, G. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000701 · Cited by 463
“This finding is supported by the results of a 5-year observational study in 1449 patients with type 2 diabetes and normal kidney function [84].”
ResultHyperuricaemia and gout in cardiovascular, metabolic and kidney disease
Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., & Tsioufis, K. P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.006 · Cited by 435
Markers of and Risk Factors for the Development and Progression of Diabetic Kidney Disease
MacIsaac, R. J., Ekinci, E. I., & Jerums, G. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.048 · Cited by 378
Li, L., Yang, C., Zhao, Y., Zeng, X., Liu, F., & Fu, P. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-122 · Cited by 371
Sircar, D., Chatterjee, S., Waikhom, R., Golay, V., Raychaudhury, A., Chatterjee, S., & Pandey, R. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.05.017 · Cited by 314
“In a cohort of patients with type 2 diabetes without overt proteinuria, hyperuricemia was found to be associated with the development of CKD.(13) Hyperuricemia has also been linked to contrast-induced acute kidney injury,(14) associated with the prevalence of left ventricular”
BackgroundInfluentialUric Acid as a Target of Therapy in CKD
Jalal, D. I., Chonchol, M., Chen, W., & Targher, G. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.021 · Cited by 268
Self-citationCui, X., Qian, D.-W., Jiang, S., Shang, E.-X., Zhu, Z.-H., & Duan, J.-A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113634 · Cited by 246
“X nthosine, a nucl oside derived from the puri base xanthine and ribose, was elevated in T2DM rats and catabolism of xanthosine could ultimately lead to the p oduction of high uric acid which was linked to diabetic complications [67,68].”
BackgroundHow to prevent the microvascular complications of type 2 diabetes beyond glucose control
Valencia, W. M., & Florez, H. (2017) · BMJ · doi:10.1136/bmj.i6505 · Cited by 233
Spiga, R., Marini, M. A., Mancuso, E., Di Fatta, C., Fuoco, A., Perticone, F., Andreozzi, F., Mannino, G. C., & Sesti, G. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309128 · Cited by 209
Clinical predictive factors in diabetic kidney disease progression
Radcliffe, N. J., Seah, J., Clarke, M., MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12533 · Cited by 208
Kim, S.-M., Lee, S.-H., Kim, Y.-G., Kim, S.-Y., Seo, J.-W., Choi, Y.-W., Kim, D.-J., Jeong, K.-H., Lee, T.-W., Ihm, C.-G., et al. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00637.2014 · Cited by 204
“In contrast to the outdated concept that hyperuricemia is simply a consequence of metabolic syndrome, recent clinical studies have demonstrated that hyperuricemia is an independent risk factor for chronic kidney disease in type 2 diabetes (2, 41).”
ResultHyperuricemia as a trigger of immune response in hypertension and chronic kidney disease
Ponticelli, C., Podestà, M. A., & Moroni, G. (2020) · Kidney International · doi:10.1016/j.kint.2020.05.056 · Cited by 192
Uric acid and inflammation in kidney disease
Jung, S. W., Kim, S.-M., Kim, Y. G., Lee, S.-H., & Moon, J.-Y. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00272.2019 · Cited by 190
“Since intrarenal macrophage accumulation is closely correlated with a rapid loss of kidney function in human and mouse diabetic kidneys (18, 104), these experimental results could be translated into the clinical finding that hyperuricemia is associated with GFR decline in subjects with type 1 or 2 DM who have preserve…”
Jitraknatee, J., Ruengorn, C., & Nochaiwong, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-63443-4 · Cited by 184
Uric acid and the cardio‐renal effects of SGLT2 inhibitors
Bailey, C. J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13670 · Cited by 183
“5 mg/dL for men and women respectively, or allopurinol treatment) after adjusting for other variables.(28) A 4-year cohort study involving 13 964 patients with type 2 diabetes noted that elevated uric acid concentrations are strongly associated with increased risk of CKD,(102) and more rapid progression of CKD was ind…”
MethodSerum Uric Acid and Risk of CKD in Type 2 Diabetes
De Cosmo, S., Viazzi, F., Pacilli, A., Giorda, C., Ceriello, A., Gentile, S., Russo, G., Rossi, M. C., Nicolucci, A., Guida, P., et al. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03140315 · Cited by 182
“As for T2DM, so far only one longitudinal study has shown an association between SUA and development of DKD (12).”
BackgroundResultKanji, T., Gandhi, M., Clase, C. M., & Yang, R. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0047-z · Cited by 174
“Hyperuricemia has also consistently been associated with incident CKD, though its association with progression of CKD has been less clear [5-27].”
BackgroundWang, W., Ding, X., Gu, T.-T., Song, L., Li, J., Xue, Q., & Kong, L. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.02.029 · Cited by 163
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Sen, T., & Heerspink, H. J. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.016 · Cited by 161
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Verzola, D., Ratto, E., Villaggio, B., Parodi, E. L., Pontremoli, R., Garibotto, G., & Viazzi, F. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115210 · Cited by 155
the Italian Diabetes Society and the Italian Society of Nephrology, Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2020) · Journal of Nephrology · doi:10.1007/s40620-019-00650-x · Cited by 125
Uric Acid as a Biomarker and a Therapeutic Target in Diabetes
Lytvyn, Y., Perkins, B. A., & Cherney, D. Z. I. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.10.013 · Cited by 152
on behalf of the PERL Consortium, Maahs, D. M., Caramori, L., Cherney, D. Z. I., Galecki, A. T., Gao, C., Jalal, D., Perkins, B. A., Pop-Busui, R., Rossing, P., et al. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0381-0 · Cited by 138
“Secondary outcomes will include: (1) The GFR at the end of the washout period (to test for effect durability); (2) Estimated GFR (eGFR) time trajectory estimated from quarterly serum creatinine and cystatin C measurements using the CKDEPI SCr and the CKD-EPI SCr-SCysC equations [80, 81]; (3) Time to doubling of baseli…”
BackgroundInfluentialDietary Antioxidant Supplements and Uric Acid in Chronic Kidney Disease: A Review
Roumeliotis, S., Roumeliotis, A., Dounousi, E., Eleftheriadis, T., & Liakopoulos, V. (2019) · Nutrients · doi:10.3390/nu11081911 · Cited by 149
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.003 · Cited by 143
Koye, D. N., Shaw, J. E., Reid, C. M., Atkins, R. C., Reutens, A. T., & Magliano, D. J. (2017) · Diabetic Medicine · doi:10.1111/dme.13324 · Cited by 140
Lu, Y., Chang, Y., Li, T., Han, F., Li, C., Li, X., Xue, M., Cheng, Y., Meng, Z., Han, Z., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.33007 · Cited by 137
“HUA is confirmed as an independent risk factor for kidney diseases [20-22], and chronic kidney disease (CKD) is a common comorbidity in T2DM [3, 23].”
BackgroundLiu, P., Chen, Y., Wang, B., Zhang, F., Wang, D., & Wang, Y. (2015) · Clinical Endocrinology · doi:10.1111/cen.12673 · Cited by 126
Renal effects of uric acid: hyperuricemia and hypouricemia
Park, J. H., Jo, Y. S., & Lee, J.-H. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.410 · Cited by 134
Fructose and uric acid in diabetic nephropathy
Bjornstad, P., Lanaspa, M. A., Ishimoto, T., Kosugi, T., Kume, S., Jalal, D. I., Maahs, D. M., Snell‐Bergeon, J. K., Johnson, R. J., & Nakagawa, T. (2015) · Diabetologia · doi:10.1007/s00125-015-3650-4 · Cited by 127
“USA 1,449 Type 2 5 years Incident CKD [13]”
BackgroundInfluentialTuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123
“Hyperuricemia may induce kidney inflammation and has been reported to be a risk factor for incident DKD in T2DM (43).”
BackgroundXu, Y., Zhu, J., Gao, L., Liu, Y., Shen, J., Shen, C., Matfin, G., & Wu, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078206 · Cited by 117
“As regards to DN, epidemiological research showed consistent results of a significant correlation between SUA concentration and nephropathy in T2DM [18,19,22,25].”
Zhao, X., Guo, S., Lu, Y., Hua, Y., Zhang, F., Yan, H., Shang, E., Wang, H., Zhang, W., & Duan, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109559 · Cited by 108
Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study
U., A. K. A., Browne, L., Li, X., Adeeb, F., Pérez-Ruiz, F., Fraser, A. D., & Stack, A. G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198197 · Cited by 107
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103
“Zoppini et al observed that the incidence of CKD more than doubled in the presence of elevated serum uric acid.(109) Another study found a similar associated risk between serum uric acid level and CKD, but also found that higher levels encouraged more rapid CKD progression.”
BackgroundTime to target uric acid to retard CKD progression
Kumagai, T., Ota, T., Tamura, Y., Chang, W., Shibata, S., & Uchida, S. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1288-2 · Cited by 99
Gu, L., Huang, L., Wu, H., Lou, Q., & Bian, R. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116680318 · Cited by 95
Novel biomarkers of diabetic kidney disease: current status and potential clinical application
Barutta, F., Bellini, S., Canepa, S., Durazzo, M., & Gruden, G. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01656-9 · Cited by 94
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Schönberger, E., Mihaljević, V., Steiner, K., Šarić, S., Kurevija, T., Majnarić, L. T., Bilić-Čurčić, I., & Canecki-Varžić, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20176671 · Cited by 93
“Uric acid, the end product of purine metabolism in the human body, has been associated with the development of cardiovascular (CV) disease [80–82], heart failure (HF) [83], metabolic syndrome [84], and chronic kidney disease [85,86].”
BackgroundBartáková, V., Kuricová, K., Pácal, L., Nová, Z., Dvořáková, V., Švrčková, M., Malúšková, D., Svobodová, I., Řehořová, J., Svojanovský, J., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.002 · Cited by 88
Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial
Eleftheriadis, T., Golfinopoulos, S., Pissas, G., & Stefanidis, I. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.05.001 · Cited by 88
Hyperuricaemia: more than just a cause of gout?
Katsiki, N., Karagiannis, A. I., Athyros, V. G., & Mikhailidis, D. P. (2012) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283595adc · Cited by 87
Liu, J., Wang, C., Liu, F., Lu, Y., & Cheng, J. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8481-0 · Cited by 86
“Although the close relationship between UA and increased risk of DN in T1DM and T2DM patients has been reported [19, 20], its specific mechanism leading to renal injury remains unclear.”
BackgroundChen, X., Hocher, C., Shen, L., Krämer, B. K., & Hocher, B. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00177.2023 · Cited by 84
Shi, W., Li, J., Wu, J., Wei, Q., Chen, C., Bao, N., Yu, C., & Gu, H. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02860-w · Cited by 81
Petrović, D., Pivin, E., Ponte, B., Dhayat, N. A., Pruijm, M. T., Ehret, G., Ackermann, D., Guessous, I., Younes, S. E., Péchère-Bertschi, A., et al. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.02.003 · Cited by 79
“…marker was dichotomized into high versus lowrisk values (1–0) according to clinical thresholds as found in the literature (Ascaso et al., 2003; Dowd and Goldman, 2006; Dowd et al., 2009; Karlamangla et al., 2012; Krishnamurthy, 2013; Perk et al., 2012; Ridker, 2003; Zoppini et al., 2012).”
Yan, D., Tu, Y., Jiang, F., Wang, J., Zhang, R., Sun, X., Wang, T., Wang, S., Bao, Y., Hu, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129797 · Cited by 78
“During a 5-year follow-up of 1,449 type 2 diabetic patients with normal kidney function, hyperuricaemia was identified as an independent risk factor for the development of DKD [19].”
BackgroundOkamura, T., Hashimoto, Y., Hamaguchi, M., Obora, A., Kojima, T., & Fukui, M. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01729-2 · Cited by 77
Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Mastrocola, R., Aragno, M., Alloatti, G., Collino, M., Penna, C., & Pagliaro, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170407123522 · Cited by 76
“Hyperuricemia is an important aspect of MS associated to the progression of renal failure [97].”
BackgroundNew progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Riaz, M., Kury, L. T. A., Atzaz, N., Alattar, A., Alshaman, R., Shah, F. A., & Li, S. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s343978 · Cited by 74
“7 10 Several studies also established a direct link between hyperuricemia and obesity or hypertension.”
BackgroundFerreira, J. P., Inzucchi, S. E., Mattheus, M., Meinicke, T. W., Steubl, D., Wanner, C., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14559 · Cited by 71
Uric Acid and Diabetic Nephropathy Risk
Mauer, M. S., & Doria, A. (2018) · Contributions to nephrology · doi:10.1159/000484284 · Cited by 70
Chang, Y., Lei, C., Lin, K., Chang, D., Hsieh, C., & Lee, Y. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2768 · Cited by 66
“[4] demonstrated that baseline hyperuricemia predicted”
BackgroundDiabetic nephropathy: newer therapeutic perspectives
Keri, K., Samji, N. S., & Blumenthal, S. S. (2018) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2018.1500423 · Cited by 70
Kim, W. J., Kim, S. S., Bae, M. J., Yi, Y., Jeon, Y. K., Kim, B. H., Song, S. H., Kim, I. J., & Kim, Y. K. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.11.006 · Cited by 64
“They showed that a 1 ± standard deviation increase in uric acid was associated with a 21% increased incidence of CKD (Zoppini et al., 2012).”
BackgroundInfluentialThe Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function
Bove, M., Cicero, A. F. G., & Borghi, C. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0793-3 · Cited by 62
Castoldi, G., Gioia, C. R. T. D., Bombardi, C., Maestroni, S., Carletti, R., Steckelings, U. M., Dahlöf, B., Unger, T., Zerbini, G., & Stella, A. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00247.2014 · Cited by 61
Hu, Y., Qing-e, L., Min, R., Deng, Y., Xu, Y., & Gao, L. (2021) · PeerJ · doi:10.7717/peerj.10691 · Cited by 61
“, 2012a) Mounting studies have demonstrated that elevated SUA is an independent risk factor for the incidence of DN (Hayashino et al., 2016; Zoppini et al., 2012).”
BackgroundLiu, H., Cui, B., & Zhang, Z. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111408 · Cited by 59
Hyperuricemia and chronic kidney disease: an enigma yet to be solved
Dousdampanis, P., Trigka, K., Musso, C. G., & Fourtounas, C. (2014) · Renal Failure · doi:10.3109/0886022x.2014.947516 · Cited by 58
“The authors concluded that HUA is an independent risk factor for the development of CKD in type 2 diabetic patient.(66) Additionally, Kim et al.”
BackgroundDrug repurposing in kidney disease
Panchapakesan, U., & Pollock, C. A. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.026 · Cited by 57
Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy?
Koçak, M. Z., Aktaş, G., Duman, T. T., Tel, B. M. A., & Şavlı, H. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.9.1156 · Cited by 56
Mende, C. W. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0272-7 · Cited by 56
“A multivariate analysis in this population of patients with T2DM confirmed that hyperuricemia, together with older age, use of antihypertensive drugs, and lower eGFR and higher albuminuria at baseline, was an independent risk factor for the development of CKD [9].”
Effect of Eurycoma longifolia Stem Extract on Uric Acid Excretion in Hyperuricemia Mice
Bao, R., Liu, M., Wang, D., Wen, S., Yu, H., Zhong, Y., Zheng, L., Zhang, Y., & Wang, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01464 · Cited by 53
Lee, J., Yang, I.-H., Kuo, H., Chung, M.-S., Chen, Y., Chen, C.-H., & Liu, R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.07.027 · Cited by 53
“[23] Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, et al.”
BackgroundSun, J., Su, H., Lou, Y., & Wang, M. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.07.020 · Cited by 52
Uric acid and chronic kidney disease: A time to act?
Bellomo, G. (2013) · World Journal of Nephrology · doi:10.5527/wjn.v2.i2.17 · Cited by 52
The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems
Agnoletti, D., Cicero, A. F. G., & Borghi, C. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.009 · Cited by 51
Barman, Z., Hasan, M., Miah, R., Mou, A. D., Hafsa, J. M., Trisha, A. D., Mahmud, F., & Ali, N. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01304-7 · Cited by 50
“as an increased risk of CKD after adjusting for sex, age, BMI, smoking status, diabetes, blood pressure and albumin[42].”
BackgroundNacak, H., van Diepen, M., Qureshi, A. R., Carrero, J. J., Stijnen, T., Dekker, F. W., & Evans, M. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv225 · Cited by 48
Comorbidities in Patients with Crystal Diseases and Hyperuricemia
Sattui, S. E., Singh, J. A., & Gaffo, A. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.01.005 · Cited by 48
An association of smoking with serum urate and gout: A health paradox
Fanning, N., Merriman, T. R., Dalbeth, N., & Stamp, L. K. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.11.004 · Cited by 48
Advanced glycation end products and diabetes and other metabolic indicators
Jiang, T., Zhang, Y., Dai, F., Liu, C., Hu, H., & Zhang, Q. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00873-2 · Cited by 45
“5 mg/dL) in women or if they were treated with allopurinol to lower UA levels [21].”
BackgroundSalinero-Fort, M. Á., Andrés-Rebollo, F. J. S., de Burgos‐Lunar, C., Gómez‐Campelo, P., Chico-Moraleja, R. M., López‐de‐Andrés, A., Jiménez‐García, R., & MADIABETES Group (2015) · PLoS ONE · doi:10.1371/journal.pone.0122030 · Cited by 43
“Also, a recent analysis of 1,449 patients with T2DM performed within the framework of the Verona Diabetes Study [25] reported a 13.”
BackgroundInfluentialPrognostic clinical and molecular biomarkers of renal disease in type 2 diabetes
Pena, M. J., de Zeeuw, D., Mischak, H., Jankowski, J., Oberbauer, R. W., Woloszczuk, W., Benner, J., Dallmann, G., Mayer, B., Mayer, G. J., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv252 · Cited by 42
Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Roy, S., Dhaneshwar, S. S., & Bhasin, B. (2021) · Current Drug Research Reviews · doi:10.2174/2589977513666210211163711 · Cited by 42
Ji, P., Zhu, J., Feng, J., Li, H., Qiao, Y., Qin, H., Wei, L., & Zhang, J. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.03.003 · Cited by 42
Komers, R., Xu, B., Schneider, J. A., & Oyama, T. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13527 · Cited by 42
“The nephroprotective potential of XOi has been shown in various models of CKD (Kang et al., 2002; Kosugi et al., 2009; Omori et al., 2012; Ryu et al., 2013; Sanchez-Lozada et al., 2008b; SanchezLozada et al., 2008c).”
BackgroundInfluentialTherapies on the Horizon for Diabetic Kidney Disease
Khan, S. S., & Quaggin, S. E. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0685-3 · Cited by 41
Zhou, F., Yu, G., Wang, G., Liu, Y., Zhang, L., Wang, W., & Chen, N. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01705-w · Cited by 41
Xia, Q., Zhang, S., Yang, S., Zhu, X., Su, S., Hu, A.-P., Zhu, J., & Li, D. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000285 · Cited by 41
Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies
Bjornstad, P., Cherney, D. Z. I., Maahs, D. M., & Nadeau, K. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0708-0 · Cited by 41
Huang, X., Ding, L., Peng, K., Lin, L., Wang, T., Zhao, Z., Xu, Y., Lu, J., Chen, Y., Wang, W., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1081-8 · Cited by 38
“73 m2 or urinary ACR ≥30 mg/g at the followup visit [26].”
Xie, S., Huang, L., Cao, W., Hu, Y., Sun, H., Cao, L., Liu, K., & Liu, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214728 · Cited by 37
Liu, P., Liu, R., Chen, X., Chen, Y., Wang, D., Zhang, F., & Wang, Y. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1094044 · Cited by 36
She, D., Xu, W., Liu, J., Zhang, Z., Fang, P., Li, R., Kong, D., Xuan, M., Liu, Q., Pan, M. Y., et al. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s427070 · Cited by 36
Wang, J., Yu, Y., Li, X., Dong, L., Xu, C., Yuan, J., Wei, S., Li, X., YANG, K. Y., Zheng, D., et al. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3046 · Cited by 36
“73 m(2)) and overt proteinuria in T2D patients.(7) Kim et al also”
BackgroundCorrelation between Serum Uric Acid Level and Microalbuminuria in Type-2 Diabetic Nephropathy
Latif, H., Iqbal, A., Rathore, R., & Butt, N. F. (2017) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.336.13224 · Cited by 34
Uric acid and risk of diabetic kidney disease
Mauer, M. S., & Doria, A. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00796-z · Cited by 34
Momoki, K., Kataoka, H., Moriyama, T., Mochizuki, T., & Nitta, K. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.37523 · Cited by 33
Guarda, N. D. S., Bollick, Y. S., de Carvalho, J. A. M., Premaor, M. O., Comim, F. V., & Moresco, R. N. (2019) · Disease Markers · doi:10.1155/2019/6025804 · Cited by 32
“Interestingly, uric acid appears to play a key role both in inflammation and in kidney damage [32, 43].”
BackgroundImpact of Uric Acid Levels on Kidney Disease Progression
Rincon-Choles, H., Jolly, S. E., Arrigain, S., König, V., Schold, J. D., Nakhoul, G., Navaneethan, S. D., Nally, J. V., & Rothberg, M. B. (2017) · American Journal of Nephrology · doi:10.1159/000481460 · Cited by 31
Geletu, A., Teferra, A. S., Sisay, M. M., & Teshome, D. F. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3618-9 · Cited by 30
the PREPARE-2 study group, Nacak, H., van Diepen, M., de Goeij, M. C. M., Rotmans, J. I., & Dekker, F. W. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-91 · Cited by 30
Kumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Ahmed, M. A., Ferede, Y. M., & Takele, W. W. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263138 · Cited by 29
Luo, Q., Cai, Y., Zhao, Q., Tian, L., Liu, Y., & Liu, W. J. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2068443 · Cited by 29
“[20] found that the incidence of diabetic nephropathy in a uric acid group was significantly higher than that in a normal uric acid group.”
Background
Metadata
- Authors
- Zoppini, G., Targher, G., Chonchol, M., Ortalda, V., Abaterusso, C., Pichiri, I., Negri, C., & Bonora, E.
- Affiliations
- University of Verona (IT)
- Division of Renal Diseases and Hypertension, University of Colorado, Aurora, Colorado
- Corresponding author
- Targher, Giovanni
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-12-09
- Volume
- 35
- Issue
- 1
- Pages
- 99-104
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3241303
- OpenAlex
- W2151157525
- Cited by
- 274
- References
- 35
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 19 · 2023: 22 · 2022: 21 · 2021: 27 · 2020: 19 · 2019: 24 · 2018: 24 · 2017: 19 · 2016: 14 · 2015: 24 · 2014: 13 · 2013: 14 · 2012: 11
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- serum uric acid, hyperuricemia, chronic kidney disease, type 2 diabetes, preserved renal function, incident CKD risk, estimated glomerular filtration rate, albuminuria, proteinuria, risk factors
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Italy, Kidney Failure, Chronic, Male, Middle Aged, Risk Factors, Uric Acid, Hyperuricemia, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
